Metoprolol Succinate

ApprovedSmall molecule

Metoprolol Succinate is a small molecule that works as a Beta-1 Adrenergic Receptor Antagonist.[2] It is being used across 24 indications, with its most advanced program in Approved.[1]

Metoprolol Succinate is one of 535 small molecule programs targeting Mitral regurgitation. It is currently in Approved.

Indications

Total Trials

Active Trials

534

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

StrokeUnknown

CardiomyopathyActive, not recruiting

Angina PectorisUnknown

Aortic StenosisActive, not recruiting

TachycardiaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Myocardial InfarctionUnknown

Oxidative StressActive, not recruiting

Congestive Heart FailureUnknown

Mitral RegurgitationApproved

Active, not recruiting

StrokePreclinical

Unknown

CardiomyopathyPhase 3

Active, not recruiting

Angina PectorisPreclinical

Unknown

Aortic StenosisPhase 2

Active, not recruiting

TachycardiaPhase 1

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 3

Active, not recruiting

Myocardial InfarctionPreclinical

Unknown

Oxidative StressApproved

Active, not recruiting

Congestive Heart FailurePreclinical

Unknown

Showing 10 of 24 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Metoprolol Succinate

AstraZeneca

Approved

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Aldactone

Pfizer

Preclinical

1 4

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 5

Tpa

UUniversity of Florida

Preclinical

1 6

Other Tkis

Bayer

Preclinical

1 7

Serology

UUniversity Hospital Center of Martinique

Preclinical

3 8

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

1 9

Dornase Alfa Inhalant Product

UUniversity Hospital, Strasbourg, France

Preclinical

1 10

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Heart Failure

NCT04996550

Phase 3Recruiting

Cardiovascular

NCT05931276

Q3 2029

ApprovedRecruiting

Heart Failure With Reduced Ejection Fraction

NCT07490067

Q3 2031

Post-ApprovalRecruiting

Heart Failure

NCT06964464

Q4 2035

Post-ApprovalActive, not recruiting

Myocardial Infarction

NCT03778554

Clinical

Trials by Indication[1]

Hypertension6 trials

COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

Completed· GSK logo

GSK·Phase 3·NCT00273052·514 enrolled

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

Completed·UUniversity of Pennsylvania·Phase 4·NCT04434664·50 enrolled

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02242812·24 enrolled

Show 3 more trials

Sympathetic Nervous System Modulation in Hypertension

Terminated·UUniversity of Cincinnati·Phase 4·NCT00491387·24 enrolled

Black Education and Treatment of Hypertension (BEAT HTN)

Completed·—·Phase 4·NCT00661895·99 enrolled

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT01970059·302 enrolled

Heart Failure5 trials

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Recruiting·UUniversity of Rochester·Phase 4·NCT06964464·2,000 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure

Terminated· Gilead logo

Gilead·Phase 3·NCT00077948·175 enrolled

Show 2 more trials

Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction

Not yet recruiting·OOdense University Hospital··NCT04996550·5,600 enrolled

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02012075·316 enrolled

Hypertensive5 trials

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00255502·100 enrolled

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00255528·144 enrolled

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01501929·32 enrolled

Show 2 more trials

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01502787·46 enrolled

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

Terminated·MMayo Clinic·Phase 4·NCT01605370·1 enrolled

Cardiomyopathy2 trials

The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.

Completed·SSteen Hvitfeldt Poulsen·Phase 2·NCT03532802·30 enrolled

The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD

Recruiting·MMedical University of Gdansk·Phase 3·NCT05066633·150 enrolled

Myocardial Infarction2 trials

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)

Active, not recruiting·KKarolinska Institutet·Phase 4·NCT03278509·5,000 enrolled

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Active, not recruiting·—·Phase 4·NCT03778554·2,760 enrolled

23 more indications

Efficacy and Safety2 trials

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05767346·175 enrolled

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

Completed·SSumitomo Pharma (Suzhou) Co., Ltd.·Phase 4·NCT02612298·198 enrolled

Cirrhosis1 trial

Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis

Completed·UUniversity of Sao Paulo·Phase 3·NCT01676285·125 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Terminated·UUniversity of Minnesota·Phase 3·NCT02587351·532 enrolled

Gene Expression1 trial

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

Completed·UUniversity of Colorado, Denver·Phase 4·NCT01798992·56 enrolled

Endothelial Function1 trial

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function

Completed·BBerlin-Chemie AG Menarini Group·Phase 4·NCT01248338·80 enrolled

Mitral regurgitation1 trial

A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.

Completed·MMayo Clinic·Phase 4·NCT00166400·60 enrolled

Tachycardia1 trial

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

Terminated·HHackensack Meridian Health·Phase 1·NCT05096884·14 enrolled

Quality of Life1 trial

The Impact of Nebivolol Versus Metoprolol on Quality of Life

Terminated·—·N/A·NCT01441570·11 enrolled

Atrial Fibrillation1 trial

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Completed·AARCA Biopharma, Inc.·Phase 2·NCT01970501·267 enrolled

Peripheral Arterial Disease1 trial

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Completed·TThomas Jefferson University·Phase 3·NCT01499134·17 enrolled

Effectiveness1 trial

Pharmacogenetic Prediction of Metoprolol Effectiveness

Terminated·UUniversity of Colorado, Denver·N/A·NCT02293096·462 enrolled

Hemodialysis1 trial

Evaluation of Metoprolol Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

Completed·UUniversity of Michigan··NCT03612180·8 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions

Completed·—·Phase 1·NCT01673997·48 enrolled

Cardiovascular1 trial

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting·VVA Office of Research and Development·Phase 3·NCT05931276·2,540 enrolled

COVID-191 trial

Medicine-induced Cardiac Hemodialysis on COVID-19

Completed·YYang I. Pachankis·Phase 4·NCT05711810·1 enrolled

Oxidative Stress1 trial

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

Completed·EEmory University·Phase 4·NCT01041287·96 enrolled

Cardiac Dysfunction1 trial

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT01052428·38 enrolled

Heart1 trial

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Completed·SSaniona·Phase 1·NCT03488719·37 enrolled

Hypotensive Anesthesia1 trial

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries

Recruiting·—·Phase 4·NCT04914234·60 enrolled

MPA1 trial

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02264002·119 enrolled

Heart Disease1 trial

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina

Completed·SShiyan City Renmin Hospital·N/A·NCT07074834·102 enrolled

Heart Failure With Reduced Ejection Fraction1 trial

Personalizing Heart Failure Treatment With Genomics: A Clinical Trial to Understand the Mechanisms and Validate a Polygenic Risk Score for Beta-Blocker Response

Recruiting·UUniversity of Michigan·Approved·NCT07490067·100 enrolled

Unspecified3 trials

Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition

Completed·—·Phase 1·NCT01694797·48 enrolled

Factorial Study of Metoprolol Succinate TOPROL-XL (324A)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00642096·1,900 enrolled

Weak Pulse at Yang and Wiry Pulse at Yin Theory

Completed·XXikun Li·N/A·NCT07378228·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 46 trial records for Metoprolol Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metoprolol Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metoprolol Succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Beta-1 Adrenergic Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Metoprolol Succinate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Q3 2031

Q4 2035

Trials by Indication[1]

Hypertension6 trials

Heart Failure5 trials

Hypertensive5 trials

Cardiomyopathy2 trials

Myocardial Infarction2 trials

Efficacy and Safety2 trials

Cirrhosis1 trial

Chronic Obstructive Pulmonary Disease1 trial

Gene Expression1 trial

Endothelial Function1 trial

Mitral regurgitation1 trial

Tachycardia1 trial

Quality of Life1 trial

Atrial Fibrillation1 trial

Peripheral Arterial Disease1 trial

Effectiveness1 trial

Hemodialysis1 trial

Fasting Conditions1 trial

Cardiovascular1 trial

COVID-191 trial

Oxidative Stress1 trial

Cardiac Dysfunction1 trial

Heart1 trial

Hypotensive Anesthesia1 trial

MPA1 trial

Heart Disease1 trial

Heart Failure With Reduced Ejection Fraction1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News